Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types

Conditions:   Carcinoma, Renal Cell;   Head and Neck Neoplasm;   Skin Neoplasms;   Microsatellite Instability;   Penile Neoplasms
Intervention:   Drug: Nivolumab
Sponsors:   UNICANCER;   National Cancer Institute, France;   Ligue contre le cancer, France;   Bristol-Myers Squibb
Not yet recruiting - verified January 2017

http://ift.tt/2jbsQeH